Anti-Infective Drugs Market

Q: What will be the CAGR of the global anti-infective drugs industry during the forecast period?

The CAGR is anticipated to be 3.2% from 2025 to 2035 Read More

Anti-Infective Drugs Market (Drug Class: Antibacterials, Anti-fungals, Antivirals, and Others; Drug Availability: Over-the-counter and Prescription; and Route of Administration: Oral, Parenteral, Topical, Rectal/Vaginal, Nasal, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

Anti-Infective Drugs Market Outlook 2035

The global anti-infective drugs industry was valued at US$ 132.6 Bn in 2024
The global anti-infective drugs market is projected to grow at a CAGR of 3.2% from 2025 to 2035 and cross US$ 187.5 Bn by the end of 2035

Analysts’ Viewpoint regarding Anti-Infective Drugs Market

The anti-infective drug market is witnessing an upward trajectory as scientific technology advancements toward the development of therapeutic agents become more universally accepted. Successful pharmaceutical R&D efforts have led to launching new drugs, drug combinations, and equipped drugs to achieve better patient outcomes and lower side effects.

Anti Infective Drugs Market By Revenue

Public health initiatives, which are focused on increasing access to essential anti-infective treatments, receive substantial funding from governments and global health organizations, especially for low- and middle-income countries. The market growth results from the combination of innovative solutions with broader accessibility, which enables more patients worldwide to benefit from advanced treatment options.

A significant contributor to the target market expansion is resistance to antibiotics, which has created an urgent need for new anti-infective agents. Studies are speeding up to develop next-generation antimicrobials, antivirals, and antifungals with improved efficacy to evict microbial resistance.

Current trends in the anti-infective drug market highlight the tremendous upheaval in drug development and the ongoing reliance on new technologies such as artificial intelligence and machine learning, thereby allowing for the identification of new candidates, shortening timelines for the discovery of new candidates, and fast-tracking trial performance.

Furthermore, interest in oral and long-acting injectable drugs is increasing firmly in order to enhance patient compliance. Also, the market continues to grow in terms of interest in directly acting microbiome therapies and immunotherapies that take advantage of the body's own defense against infection.

The competitiveness of the anti-infective drug market is poised to be bolstered by specific strategic efforts characterized by the major players utilizing technologies to remain relevant to the market. Companies are adopting new drugs from early discovery through preclinical development and to go to market in record time and true to intended indications with optimal patient outcomes.

Companies are utilizing digital health systems to increase patient monitoring and help facilitate clinical trials. Apart from addressing the short-term requirement for novel anti-infective medications globally, these forward-thinking strategies are enabling business contestants to stay in the competition.

Anti-Infective Drugs Market Introduction

Anti-infective drugs are the medications used to treat any disease/infection that are caused by pathogens. These include antiviral, antibiotic, antifungal, and antiparasitic medications, which have their own specific mechanism of action for specifically targeting individual pathogens.

Such drugs kill the invading pathogens or stop them from multiplying so that the immune system in the body can effectively plunder them. By reducing the duration and intensity of infection, these medicines are instrumental in lessening mortality and morbidity worldwide.

The best-known category of anti-infective agent continues to be antibiotics, which are used at regular intervals for treating bacterial infections from mild respiratory syndromes to fatal sepsis.

Antibiotics target bacteria by disruption of critical functions of bacteria such as protein production or cell wall synthesis. Antivirals, on the other hand, are deployed for inhibiting viruses from replicating and hence have a vital role to play in disease control if one considers HIV, influenza, and hepatitis.

Anti-infective drugs have succeeded in one way to transform modern medicine. The possibility of organ transplantation, chemotherapy, and surgeries once presented a significant risk for infections that until the use of anti-infective drugs was previously impossible in medicine, but these procedures can now be performed safely because of anti-infective drugs.

Anti-infective drugs work in conjunction with vaccination programs to limit the risk of infection with an entire population. The prophylactic use of anti-infective drugs is essential for individuals at-risk for infection such as individuals undergoing surgery or individuals who are immunocompromised.

On the other hand, the application of anti-infective drugs is incessantly limited by the emergence of resistant strains of pathogens. One of the leading contributors to drug resistance is misuse/overuse and incomplete treatment. Resistance limits the use of many existing therapies.

As a continuing threat, there is a growing need for continuous research around new classes of drugs and new therapeutic strategies. Several advances in therapeutic strategy consider resistance in anti-infectives’, particularly combination therapies, mechanisms to employ targeted drug delivery systems, and immune modulating-based therapies. These strategies are meaningful advances to countering threats to anti-infective. Anti-infectives remain essential methods in progress towards protecting the health of populations and combating the burden of changing infectious threats.

Attribute	Detail
Anti-Infective Drugs Market Drivers	Rising Prevalence of Infectious Disease Rising Aging Population

Rising Prevalence of Infectious Diseases Skyrocketing Anti-Infective Drugs Market Share

The increasing incidence of infectious diseases drives the anti-infective drugs market. New pathogens are being recognized and previously controlled infections are re-emerging, and healthcare systems are becoming overstressed across the globe. Urbanization, climate change, and antibiotic resistance combine to fuel the number of pathogens causing infectious disease and the need for better and newer treatment options. Companies are investing their resources into finding new anti-infectives including antibiotics, antivirals, antifungals.

The combination of rising urban population and international travel along with inadequate sanitation in certain areas has escalated infection transmission, which creates higher needs for efficient medical treatments. Healthcare management at all stages depends heavily on anti-infective drugs because of the increasing disease burden.

Healthcare systems need extensive antibiotic use to handle bacterial infections, including pneumonia, sepsis and tuberculosis. Viral outbreaks, which include influenza together with HIV and hepatitis and recently discovered coronaviruses, demonstrate the crucial requirement for new antiviral medications.

The market maintains steady as healthcare providers need to provide immediate access to suitable drug treatments to handle outbreaks and minimize complications. The continuous high incidence of these diseases maintains a constant need for anti-infective medications.

Rising Aging Population Anticipated to Propel Anti-Infective Drugs Market Share

The rising population of elderly people drives the anti-infective drugs market as aging population faces increased infection risks due to their weakened immune systems. The immune system does decline as people grow older, so they turn out to be more prone to bacterial, fungal, and viral infections. The demographic transition creates worldwide demand for effective and affordable therapeutic solutions.

Hospitals, nursing homes, and long-term care environments are common areas of transmission due to a high potential for movement and congregation of a number of elderly patients. The increased burden of healthcare-associated infections in hospitals, long-term care screening environments, and likewise have increased consumption of antibiotics, antifungals, and antivirals.

The anti-infectives are not just used for treatment but appropriate and efficacious prophylactic therapies are used to secure older patients during procedures that could provoke infection as well, as with surgery or chemotherapy.

Drug companies and healthcare providers are acknowledging the changing numbers and supply appropriate therapy as well as dosage forms appropriate for older individuals. Longer acting injectables, oral dosage forms, and combinations of therapies, all specific to older adults, will be available to facilitate compliance and health outcomes. The growing demand from older adults as a vulnerable and rapidly growing demographic in the world population, will ensure sustained growth within the anti-infective drugs market.

Antiviral Drugs Leading Global Anti-Infective Drugs Market

Anti Infective Drugs Market By Drug Class

The anti-infective drugs market exists with antiviral drugs as its primary leader since viral infections including HIV and hepatitis and influenza havespread throughout the world. The growing incidence of these diseases has created significant market demand for antiviral treatments that reduce disease severity and mortality rates, thereby making antivirals an essential market category.

The antiviral drug sector stays at the forefront of the market owing to continuous drug development enhancements, which produce next-generation antiviral drugs that minimize side-effects while improving treatment outcomes. The increased interest in preventive healthcare combined with vaccination programs and governmental initiatives to combat viral outbreaks promotes widespread antiviral usage.

Regional Outlook of Anti-Infective Drugs Market

Anti Infective Drugs Market By Region

Attribute	Detail
Leading Region	North America

As per the latest anti-infective drugs market analysis, North America dominated in 2024. This is due to the fact that North America offers an environment where people can easily access a range of cutting-edge treatments. New medicines and formulations are continuously being made available to the public. This is possible due to the presence of a system that's open to new ideas and allows for fast approval of the latest treatments, for infections, both - old and new.

The spread of infections across hospitals in North America is a major concern having a significant impact on the market for anti-infective drugs. In order to combat the spread of healthcare-associated infection, significant investments are being made to investigate ways of tackling antibiotic resistance.

Analysis of Key Players in Anti-Infective Drugs Market

The players operating in the anti-infective drugs market are employing strategies such as investment in research and development of new therapies, building strategic partnerships, enhancing manufacturing capacities, and lowering cost of access in emerging markets. Furthermore, they are observing new technologies that permit competitive advantages for their product positioning.

Pfizer Inc., Gland Pharma Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Jiangsu Simcere Pharmaceutical Co., Ltd., Novartis AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Astellas Pharma Inc., Alkem, AstraZeneca, Johnson & Johnson Services, Inc., Sanofi, and Abbott are some of the leading players operating in the global anti-infective drugs market.

Each of these players has been profiled in the anti-infective drugs market research report based on parameters such as company overview, business strategies, financial overview, product portfolio, business segments, and recent developments.

Key Developments in Anti-Infective Drugs Market

In July 2025, Merck announced that The Food and Drug Administration of United States had accepted the New Drug Application for doravirine/islatravine (DOR/ISL). The investigational two-drug oral regimen consisting of doravirine/islatravine functions as a daily treatment for virologically suppressed adults who have HIV-1 positive.
In April 2024, Pfizer Inc. was granted authorization by The European Commission for EMBLAVEO (aztreonam-avibactam) for treating adult patients with complicated intra-abdominal infections (cIAI) as well as hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), complicated urinary tract infections (cUTI), and pyelonephritis. EMBLAVEO received approval for treating infections caused by aerobic Gram-negative organisms in adult patients who have no other suitable treatment options.

Anti-Infective Drugs Market Snapshot

Attribute	Detail
Size in 2024	US$ 132.6 Bn
Forecast Value in 2035	US$ 187.5 Bn
CAGR	3.2%
Forecast Period	2025-2035
Historical Data Available for	2020-2023
Quantitative Units	US$ Bn
Biotechnology Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis.
Competition Landscape	Competition Matrix Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Segmentation	Drug Class Antibacterials Carbapenem Biapenem Ertapenem Others (Meropenem, etc.) Penicillin Amoxicillin Ampicillin Others (Nafcillin, Oxacillin, etc.) Cephalosporins Cefprozil Cefaclor Cefdinir Others (Cefepime, Cefazolin, etc.) Tetracyclines Aminoglycosides Macrolides Azithromycin Clarithromycin Erythromycin Others (Roxithromycin, Spiramycin, etc.) Clindamycin Sulfonamides and trimethoprim Quinolones Nitrofurantoin Others (Metronidazole, Tinidazole, etc.) Anti-fungals Polyenes Azoles Allylamines Echinocandins Antivirals Adamantane 3CL-Protease Hemagglutinin Fusion Inhibitor Chemokine Receptor Antagonist Miscellaneous Antivirals Integrase Strand Transfer Inhibitor Neuraminidase Inhibitors NS5A Inhibitors Purine Nucleosides Others (NNRTIs, Antiviral Boosters, etc.) Others (Amebicides, Antihelmintics, Aminoglycosides, etc.) Drug Availability Over-the-counter Prescription Route of Administration Oral Parenteral Topical Rectal/Vaginal Nasal Others (Otic, etc.) Formulation Capsules Tablets Cream/Gels Liquid/Solution Powder Others (Pessaries, etc.) Indication Pneumonia Sepsis Tuberculosis Dermatophytosis Candidiasis Hepatitis virus infection HIV infection Covid-19 Virus Methicilin-resistant Staphylococcus Aureus Others (Aspergillosis, Candidiasis, Dermatophytosis, etc.) Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain The Netherlands China Australia & New Zealand India Japan South Korea ASEAN Brazil Mexico Argentina GCC Countries South Africa
Companies Profiled	Pfizer Inc. Gland Pharma Limited Teva Pharmaceutical Industries Ltd. F. Hoffmann-La Roche Ltd Jiangsu Simcere Pharmaceutical Co., Ltd. Novartis AG Gilead Sciences, Inc. GlaxoSmithKline plc Merck & Co., Inc. Astellas Pharma Inc. Alkem AstraZeneca Johnson & Johnson Services, Inc. Sanofi Abbott
Customization Scope	Available upon request
Pricing	Available upon request

Frequently Asked Questions

How big was the global anti-infective drugs market in 2024?

The global anti-infective drugs market was valued at US$ 132.6 Bn in 2024

How big will the global anti-infective drugs industry be in 2035?

The global anti-infective drugs industry is projected to reach more than US$ 187.5 Bn by the end of 2035

What are the factors driving the anti-infective drugs market?

The increasing prevalence of infectious diseases, the rising threat of antimicrobial resistance (AMR), and technological advancements in drug development and increasing global healthcare expenditure are some of the factors driving the expansion of anti-infective drugs market.

What will be the CAGR of the global anti-infective drugs industry during the forecast period?

The CAGR is anticipated to be 3.2% from 2025 to 2035

Who are the prominent players in the global anti-infective drugs market?

Preface
- Market Definition and Scope
- Market Segmentation
- Key Research Objectives
- Research Highlights
Assumptions and Research. Methodology
Executive Summary: Global Anti-Infective Drugs. Market
Market Overview
- Introduction
  - Segment Definition
- Overview
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunities
- Global Anti-Infective Drugs. Market Analysis and Forecast, 2020 - 2035
  - Market Revenue Projections (US$ Bn)
Key Insights
- Healthcare Expenditure across Key Regions / Countries
- Epidemiology of Infectious Diseases across Key Regions / Countries
- Technological Advancements in Anti-Infective Drugs
- Pricing Trends of Anti-infective Drugs
- Regulatory Scenario across Key Regions / Countries
- Reimbursement Landscape across Key Regions / Countries
- PORTER’s Five Forces Analysis
- PESTLE Analysis
- Go-to-Market Strategy for New. Market Entrants
- Key Purchase. Metrics for End-users
- Key Industry Events (Partnership, Collaborations, Product approvals,. Merger & acquisitions)
- Benchmarking of the Products Offered by the Leading Competitors
Global Anti-Infective Drugs. Market Analysis and Forecast, by Drug Class
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Drug Class, 2020 - 2035
  - Antibacterials
    - Carbapenem
      - Biapenem
      - Ertapenem
      - Others
    - Penicillin
      - Amoxicillin
      - Ampicillin
      - Others
    - Cephalosporins
      - Cefprozil
      - Cefaclor
      - Cefdinir
      - Others
    - Tetracyclines
    - Aminoglycosides
    - Macrolides
      - Azithromycin
      - Clarithromycin
      - Erythromycin
      - Others
    - Clindamycin
    - Sulfonamides and trimethoprim
    - Quinolones
    - Nitrofurantoin
    - Others
  - Anti-fungals
    - Polyenes
    - Azoles
    - Allylamines
    - Echinocandins
  - Antivirals
    - Adamantane
    - 3CL-Protease
    - Hemagglutinin Fusion Inhibitor
    - Chemokine Receptor Antagonist
    - Miscellaneous Antivirals
    - Integrase Strand Transfer Inhibitor
    - Neuraminidase Inhibitors
    - NS5A Inhibitors
    - Purine Nucleosides
    - Others
  - Others
- Market Attractiveness Analysis, by Drug Class
Global Anti-Infective Drugs. Market Analysis and Forecast, by Drug Availability
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Drug Availability, 2020 - 2035
  - Over-the-counter
  - Prescription
- Market Attractiveness Analysis, by Drug Availability
Global Anti-Infective Drugs. Market Analysis and Forecast, by Route of Administration
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Route of Administration , 2020 - 2035
  - Oral
  - Parenteral
  - Topical
  - Rectal/Vaginal
  - Nasal
  - Others
- Market Attractiveness Analysis, by Route of Administration
Global Anti-Infective Drugs. Market Analysis and Forecast, by Formulation
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Formulation, 2020 - 2035
  - Capsules
  - Tablets
  - Cream/Gels
  - Liquid/Solution
  - Powder
  - Others
- Market Attractiveness Analysis, by Formulation
Global Anti-Infective Drugs. Market Analysis and Forecast, by Indication
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Indication, 2020 - 2035
  - Pneumonia
  - Sepsis
  - Tuberculosis
  - Dermatophytosis
  - Candidiasis
  - Hepatitis virus infection
  - HIV infection
  - Covid-19 Virus
  - Methicilin-resistant Staphylococcus Aureus
  - Others
- Market Attractiveness Analysis, by Indication
Global Anti-Infective Drugs. Market Analysis and Forecast, by Distribution Channel
- Introduction & Definition
Key Findings/Developments
- Market Value Forecast, by Distribution Channel, 2020 - 2035
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
- Market Attractiveness Analysis, by Distribution Channel
Global Anti-Infective Drugs. Market Analysis and Forecast, by Region
Key Findings
Market Value Forecast, by Region, 2020 - 2035
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Market Attractiveness Analysis, by Region
North America Anti-Infective Drugs. Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Drug Class, 2020 - 2035
  - Antibacterials
    - Carbapenem
      - Biapenem
      - Ertapenem
      - Others
    - Penicillin
      - Amoxicillin
      - Ampicillin
      - Others
    - Cephalosporins
      - Cefprozil
      - Cefaclor
      - Cefdinir
      - Others
    - Tetracyclines
    - Aminoglycosides
    - Macrolides
      - Azithromycin
      - Clarithromycin
      - Erythromycin
      - Others
    - Clindamycin
    - Sulfonamides and trimethoprim
    - Quinolones
    - Nitrofurantoin
    - Others
  - Anti-fungals
    - Polyenes
    - Azoles
    - Allylamines
    - Echinocandins
  - Antivirals
    - Adamantane
    - 3CL-Protease
    - Hemagglutinin Fusion Inhibitor
    - Chemokine Receptor Antagonist
    - Miscellaneous Antivirals
    - Integrase Strand Transfer Inhibitor
    - Neuraminidase Inhibitors
    - NS5A Inhibitors
    - Purine Nucleosides
    - Others
  - Others
- Market Value Forecast, by Drug Availability, 2020 - 2035
  - Over-the-counter
  - Prescription
- Market Value Forecast, by Route of Administration , 2020 - 2035
  - Oral
  - Parenteral
  - Topical
  - Rectal/Vaginal
  - Nasal
  - Others
- Market Value Forecast, by Formulation, 2020 - 2035
  - Capsules
  - Tablets
  - Cream/Gels
  - Liquid/Solution
  - Powder
  - Others
- Market Value Forecast, by Indication, 2020 - 2035
  - Pneumonia
  - Sepsis
  - Tuberculosis
  - Dermatophytosis
  - Candidiasis
  - Hepatitis virus infection
  - HIV infection
  - Covid-19 Virus
  - Methicilin-resistant Staphylococcus Aureus
  - Others
- Market Value Forecast, by Distribution Channel, 2020 - 2035
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- Market Value Forecast, by Country, 2020 - 2035
  - U.S.
  - Canada
- Market Attractiveness Analysis
  - By Drug Class
  - By Drug Availability
  - By Route of Administration
  - By Formulation
  - By Indication
  - By Distribution Channel
  - By Country
Europe Anti-Infective Drugs. Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Drug Class, 2020 - 2035
  - Antibacterials
    - Carbapenem
      - Biapenem
      - Ertapenem
      - Others
    - Penicillin
      - Amoxicillin
      - Ampicillin
      - Others
    - Cephalosporins
      - Cefprozil
      - Cefaclor
      - Cefdinir
      - Others
    - Tetracyclines
    - Aminoglycosides
    - Macrolides
      - Azithromycin
      - Clarithromycin
      - Erythromycin
      - Others
    - Clindamycin
    - Sulfonamides and trimethoprim
    - Quinolones
    - Nitrofurantoin
    - Others
  - Anti-fungals
    - Polyenes
    - Azoles
    - Allylamines
    - Echinocandins
  - Antivirals
    - Adamantane
    - 3CL-Protease
    - Hemagglutinin Fusion Inhibitor
    - Chemokine Receptor Antagonist
    - Miscellaneous Antivirals
    - Integrase Strand Transfer Inhibitor
    - Neuraminidase Inhibitors
    - NS5A Inhibitors
    - Purine Nucleosides
    - Others
  - Others
- Market Value Forecast, by Drug Availability, 2020 - 2035
  - Over-the-counter
  - Prescription
- Market Value Forecast, by Route of Administration , 2020 - 2035
  - Oral
  - Parenteral
  - Topical
  - Rectal/Vaginal
  - Nasal
  - Others
- Market Value Forecast, by Formulation, 2020 - 2035
  - Capsules
  - Tablets
  - Cream/Gels
  - Liquid/Solution
  - Powder
  - Others
- Market Value Forecast, by Indication, 2020 - 2035
  - Pneumonia
  - Sepsis
  - Tuberculosis
  - Dermatophytosis
  - Candidiasis
  - Hepatitis virus infection
  - HIV infection
  - Covid-19 Virus
  - Methicilin-resistant Staphylococcus Aureus
  - Others
- Market Value Forecast, by Distribution Channel, 2020 - 2035
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - UK
  - Germany
  - France
  - Italy
  - Spain
  - The Netherlands
  - Rest of Europe
- Market Attractiveness Analysis
  - By Drug Class
  - By Drug Availability
  - By Route of Administration
  - By Formulation
  - By Indication
  - By Distribution Channel
  - By Country/Sub-region
Asia Pacific Anti-Infective Drugs. Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Drug Class, 2020 - 2035
  - Antibacterials
    - Carbapenem
      - Biapenem
      - Ertapenem
      - Others
    - Penicillin
      - Amoxicillin
      - Ampicillin
      - Others
    - Cephalosporins
      - Cefprozil
      - Cefaclor
      - Cefdinir
      - Others
    - Tetracyclines
    - Aminoglycosides
    - Macrolides
      - Azithromycin
      - Clarithromycin
      - Erythromycin
      - Others
    - Clindamycin
    - Sulfonamides and trimethoprim
    - Quinolones
    - Nitrofurantoin
    - Others
  - Anti-fungals
    - Polyenes
    - Azoles
    - Allylamines
    - Echinocandins
  - Antivirals
    - Adamantane
    - 3CL-Protease
    - Hemagglutinin Fusion Inhibitor
    - Chemokine Receptor Antagonist
    - Miscellaneous Antivirals
    - Integrase Strand Transfer Inhibitor
    - Neuraminidase Inhibitors
    - NS5A Inhibitors
    - Purine Nucleosides
    - Others
  - Others
- Market Value Forecast, by Drug Availability, 2020 - 2035
  - Over-the-counter
  - Prescription
- Market Value Forecast, by Route of Administration , 2020 - 2035
  - Oral
  - Parenteral
  - Topical
  - Rectal/Vaginal
  - Nasal
  - Others
- Market Value Forecast, by Formulation, 2020 - 2035
  - Capsules
  - Tablets
  - Cream/Gels
  - Liquid/Solution
  - Powder
  - Others
- Market Value Forecast, by Indication, 2020 - 2035
  - Pneumonia
  - Sepsis
  - Tuberculosis
  - Dermatophytosis
  - Candidiasis
  - Hepatitis virus infection
  - HIV infection
  - Covid-19 Virus
  - Methicilin-resistant Staphylococcus Aureus
  - Others
- Market Value Forecast, by Distribution Channel, 2020 - 2035
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Market Attractiveness Analysis
  - By Drug Class
  - By Drug Availability
  - By Route of Administration
  - By Formulation
  - By Indication
  - By Distribution Channel
  - By Country/Sub-region
Latin America Anti-Infective Drugs. Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Drug Class, 2020 - 2035
  - Antibacterials
    - Carbapenem
      - Biapenem
      - Ertapenem
      - Others
    - Penicillin
      - Amoxicillin
      - Ampicillin
      - Others
    - Cephalosporins
      - Cefprozil
      - Cefaclor
      - Cefdinir
      - Others
    - Tetracyclines
    - Aminoglycosides
    - Macrolides
      - Azithromycin
      - Clarithromycin
      - Erythromycin
      - Others
    - Clindamycin
    - Sulfonamides and trimethoprim
    - Quinolones
    - Nitrofurantoin
    - Others
  - Anti-fungals
    - Polyenes
    - Azoles
    - Allylamines
    - Echinocandins
  - Antivirals
    - Adamantane
    - 3CL-Protease
    - Hemagglutinin Fusion Inhibitor
    - Chemokine Receptor Antagonist
    - Miscellaneous Antivirals
    - Integrase Strand Transfer Inhibitor
    - Neuraminidase Inhibitors
    - NS5A Inhibitors
    - Purine Nucleosides
    - Others
  - Others
- Market Value Forecast, by Drug Availability, 2020 - 2035
  - Over-the-counter
  - Prescription
- Market Value Forecast, by Route of Administration , 2020 - 2035
  - Oral
  - Parenteral
  - Topical
  - Rectal/Vaginal
  - Nasal
  - Others
- Market Value Forecast, by Formulation, 2020 - 2035
  - Capsules
  - Tablets
  - Cream/Gels
  - Liquid/Solution
  - Powder
  - Others
- Market Value Forecast, by Indication, 2020 - 2035
  - Pneumonia
  - Sepsis
  - Tuberculosis
  - Dermatophytosis
  - Candidiasis
  - Hepatitis virus infection
  - HIV infection
  - Covid-19 Virus
  - Methicilin-resistant Staphylococcus Aureus
  - Others
- Market Value Forecast, by Distribution Channel, 2020 - 2035
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
- Market Attractiveness Analysis
  - By Drug Class
  - By Drug Availability
  - By Route of Administration
  - By Formulation
  - By Indication
  - By Distribution Channel
  - By Country/Sub-region
Middle East & Africa Anti-Infective Drugs. Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Drug Class, 2020 - 2035
  - Antibacterials
    - Carbapenem
      - Biapenem
      - Ertapenem
      - Others
    - Penicillin
      - Amoxicillin
      - Ampicillin
      - Others
    - Cephalosporins
      - Cefprozil
      - Cefaclor
      - Cefdinir
      - Others
    - Tetracyclines
    - Aminoglycosides
    - Macrolides
      - Azithromycin
      - Clarithromycin
      - Erythromycin
      - Others
    - Clindamycin
    - Sulfonamides and trimethoprim
    - Quinolones
    - Nitrofurantoin
    - Others
  - Anti-fungals
    - Polyenes
    - Azoles
    - Allylamines
    - Echinocandins
  - Antivirals
    - Adamantane
    - 3CL-Protease
    - Hemagglutinin Fusion Inhibitor
    - Chemokine Receptor Antagonist
    - Miscellaneous Antivirals
    - Integrase Strand Transfer Inhibitor
    - Neuraminidase Inhibitors
    - NS5A Inhibitors
    - Purine Nucleosides
    - Others
  - Others
- Market Value Forecast, by Drug Availability, 2020 - 2035
  - Over-the-counter
  - Prescription
- Market Value Forecast, by Route of Administration , 2020 - 2035
  - Oral
  - Parenteral
  - Topical
  - Rectal/Vaginal
  - Nasal
  - Others
- Market Value Forecast, by Formulation, 2020 - 2035
  - Capsules
  - Tablets
  - Cream/Gels
  - Liquid/Solution
  - Powder
  - Others
- Market Value Forecast, by Indication, 2020 - 2035
  - Pneumonia
  - Sepsis
  - Tuberculosis
  - Dermatophytosis
  - Candidiasis
  - Hepatitis virus infection
  - HIV infection
  - Covid-19 Virus
  - Methicilin-resistant Staphylococcus Aureus
  - Others
- Market Value Forecast, by Distribution Channel, 2020 - 2035
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - GCC Countries
  - South Africa
  - Rest of. Middle East & Africa
- Market Attractiveness Analysis
  - By Drug Class
  - By Drug Availability
  - By Route of Administration
  - By Formulation
  - By Indication
  - By Distribution Channel
  - By Country/Sub-region
Competition Landscape
- Market Player - Competition. Matrix (By Tier and Size of Companies)
- Market Share Analysis, by Company (2024)
- Company Profiles
  - Pfizer Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Gland Pharma Limited
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Teva Pharmaceutical Industries Ltd.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - F. Hoffmann-La Roche Ltd
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Jiangsu Simcere Pharmaceutical Co., Ltd.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Novartis AG
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Gilead Sciences, Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - GlaxoSmithKline plc
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Merck & Co., Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Astellas Pharma Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Alkem
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - AstraZeneca
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Johnson & Johnson Services, Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Sanofi
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Abbott
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments

List of Tables

Table 01: Global Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Drug Class, 2020 to 2035
Table 02: Global Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Antibacterials, 2020 to 2035
Table 03: Global Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Anti-fungals, 2020 to 2035
Table 04: Global Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Antivirals, 2020 to 2035
Table 05: Global Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Drug Availability, 2020 to 2035
Table 06: Global Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 07: Global Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Formulation, 2020 to 2035
Table 08: Global Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 09: Global Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
Table 10: Global Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
Table 11: North America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2035
Table 12: North America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Drug Class, 2020 to 2035
Table 13: North America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Antibacterials, 2020 to 2035
Table 14: North America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Anti-fungals, 2020 to 2035
Table 15: North America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Antivirals, 2020 to 2035
Table 16: North America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Drug Availability, 2020 to 2035
Table 17: North America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 18: North America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Formulation, 2020 to 2035
Table 19: North America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 20: North America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
Table 21: Europe - Anti-Infective Drugs Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 22: Europe - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Drug Class, 2020 to 2035
Table 23: Europe - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Antibacterials, 2020 to 2035
Table 24: Europe - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Anti-fungals, 2020 to 2035
Table 25: Europe - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Antivirals, 2020 to 2035
Table 26: Europe - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Drug Availability, 2020 to 2035
Table 27: Europe - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 28: Europe - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Formulation, 2020 to 2035
Table 29: Europe - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 30: Europe - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
Table 31: Asia Pacific - Anti-Infective Drugs Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 32: Asia Pacific - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Drug Class, 2020 to 2035
Table 33: Asia Pacific - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Antibacterials, 2020 to 2035
Table 34: Asia Pacific - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Anti-fungals, 2020 to 2035
Table 35: Asia Pacific - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Antivirals, 2020 to 2035
Table 36: Asia Pacific - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Drug Availability, 2020 to 2035
Table 37: Asia Pacific - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 38: Asia Pacific - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Formulation, 2020 to 2035
Table 39: Asia Pacific - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 40: Asia Pacific - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
Table 41: Latin America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 42: Latin America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Drug Class, 2020 to 2035
Table 43: Latin America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Antibacterials, 2020 to 2035
Table 44: Latin America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Anti-fungals, 2020 to 2035
Table 45: Latin America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Antivirals, 2020 to 2035
Table 46: Latin America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Drug Availability, 2020 to 2035
Table 47: Latin America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 48: Latin America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Formulation, 2020 to 2035
Table 49: Latin America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 50: Latin America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
Table 51: Middle East & Africa - Anti-Infective Drugs Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 52: Middle East & Africa - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Drug Class, 2020 to 2035
Table 53: Middle East & Africa - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Antibacterials, 2020 to 2035
Table 54: Middle East & Africa - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Anti-fungals, 2020 to 2035
Table 55: Middle East & Africa - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Antivirals, 2020 to 2035
Table 56: Middle East & Africa - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Drug Availability, 2020 to 2035
Table 57: Middle East & Africa - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 58: Middle East & Africa - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Formulation, 2020 to 2035
Table 59: Middle East & Africa - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Indication, 2020 to 2035
Table 60: Middle East & Africa - Anti-Infective Drugs Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035

List of Figures

Figure 01: Global Anti-Infective Drugs Market Value Share Analysis, By Drug Class, 2024 and 2035
Figure 02: Global Anti-Infective Drugs Market Attractiveness Analysis, By Drug Class, 2025 to 2035
Figure 03: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Antibacterials, 2020 to 2035
Figure 04: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Anti-fungals, 2020 to 2035
Figure 05: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Antivirals, 2020 to 2035
Figure 06: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 07: Global Anti-Infective Drugs Market Value Share Analysis, By Drug Availability, 2024 and 2035
Figure 08: Global Anti-Infective Drugs Market Attractiveness Analysis, By Drug Availability, 2025 to 2035
Figure 09: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Over-the-counter, 2020 to 2035
Figure 10: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Prescription, 2020 to 2035
Figure 11: Global Anti-Infective Drugs Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 12: Global Anti-Infective Drugs Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 13: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Oral, 2020 to 2035
Figure 14: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Parenteral, 2020 to 2035
Figure 15: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Topical, 2020 to 2035
Figure 16: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Rectal/Vaginal, 2020 to 2035
Figure 17: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Nasal, 2020 to 2035
Figure 18: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 19: Global Anti-Infective Drugs Market Value Share Analysis, By Formulation, 2024 and 2035
Figure 20: Global Anti-Infective Drugs Market Attractiveness Analysis, By Formulation, 2025 to 2035
Figure 21: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Capsules, 2020 to 2035
Figure 22: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Tablets, 2020 to 2035
Figure 23: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Cream/Gels, 2020 to 2035
Figure 24: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Liquid/Solution, 2020 to 2035
Figure 25: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Powder, 2020 to 2035
Figure 26: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 27: Global Anti-Infective Drugs Market Value Share Analysis, By Indication, 2024 and 2035
Figure 28: Global Anti-Infective Drugs Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 29: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Pneumonia, 2020 to 2035
Figure 30: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Sepsis, 2020 to 2035
Figure 31: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Tuberculosis, 2020 to 2035
Figure 32: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Dermatophytosis, 2020 to 2035
Figure 33: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Candidiasis, 2020 to 2035
Figure 34: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Hepatitis virus infection, 2020 to 2035
Figure 35: Global Anti-Infective Drugs Market Revenue (US$ Bn), by HIV infection, 2020 to 2035
Figure 36: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Covid-19 Virus, 2020 to 2035
Figure 37: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Methicilin-resistant Staphylococcus Aureus, 2020 to 2035
Figure 38: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 39: Global Anti-Infective Drugs Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 40: Global Anti-Infective Drugs Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Figure 41: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Hospital Pharmacies, 2020 to 2035
Figure 42: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Retail Pharmacies, 2020 to 2035
Figure 43: Global Anti-Infective Drugs Market Revenue (US$ Bn), by Online Pharmacies, 2020 to 2035
Figure 44: Global Anti-Infective Drugs Market Value Share Analysis, By Region, 2024 and 2035
Figure 45: Global Anti-Infective Drugs Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 46: North America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 47: North America - Anti-Infective Drugs Market Value Share Analysis, by Country, 2024 and 2035
Figure 48: North America - Anti-Infective Drugs Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 49: North America - Anti-Infective Drugs Market Value Share Analysis, By Drug Class, 2024 and 2035
Figure 50: North America - Anti-Infective Drugs Market Attractiveness Analysis, By Drug Class, 2025 to 2035
Figure 51: North America - Anti-Infective Drugs Market Value Share Analysis, By Drug Availability, 2024 and 2035
Figure 52: North America - Anti-Infective Drugs Market Attractiveness Analysis, By Drug Availability, 2025 to 2035
Figure 53: North America - Anti-Infective Drugs Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 54: North America - Anti-Infective Drugs Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 55: North America - Anti-Infective Drugs Market Value Share Analysis, By Formulation, 2024 and 2035
Figure 56: North America - Anti-Infective Drugs Market Attractiveness Analysis, By Formulation, 2025 to 2035
Figure 57: North America - Anti-Infective Drugs Market Value Share Analysis, By Indication, 2024 and 2035
Figure 58: North America - Anti-Infective Drugs Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 59: North America - Anti-Infective Drugs Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 60: North America - Anti-Infective Drugs Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Figure 61: Europe - Anti-Infective Drugs Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 62: Europe - Anti-Infective Drugs Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 63: Europe - Anti-Infective Drugs Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 64: Europe - Anti-Infective Drugs Market Value Share Analysis, By Drug Class, 2024 and 2035
Figure 65: Europe - Anti-Infective Drugs Market Attractiveness Analysis, By Drug Class, 2025 to 2035
Figure 66: Europe - Anti-Infective Drugs Market Value Share Analysis, By Drug Availability, 2024 and 2035
Figure 67: Europe - Anti-Infective Drugs Market Attractiveness Analysis, By Drug Availability, 2025 to 2035
Figure 68: Europe - Anti-Infective Drugs Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 69: Europe - Anti-Infective Drugs Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 70: Europe - Anti-Infective Drugs Market Value Share Analysis, By Formulation, 2024 and 2035
Figure 71: Europe - Anti-Infective Drugs Market Attractiveness Analysis, By Formulation, 2025 to 2035
Figure 72: Europe - Anti-Infective Drugs Market Value Share Analysis, By Indication, 2024 and 2035
Figure 73: Europe - Anti-Infective Drugs Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 74: Europe - Anti-Infective Drugs Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 75: Europe - Anti-Infective Drugs Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Figure 76: Asia Pacific - Anti-Infective Drugs Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 77: Asia Pacific - Anti-Infective Drugs Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 78: Asia Pacific - Anti-Infective Drugs Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 79: Asia Pacific - Anti-Infective Drugs Market Value Share Analysis, By Drug Class, 2024 and 2035
Figure 80: Asia Pacific - Anti-Infective Drugs Market Attractiveness Analysis, By Drug Class, 2025 to 2035
Figure 81: Asia Pacific - Anti-Infective Drugs Market Value Share Analysis, By Drug Availability, 2024 and 2035
Figure 82: Asia Pacific - Anti-Infective Drugs Market Attractiveness Analysis, By Drug Availability, 2025 to 2035
Figure 83: Asia Pacific - Anti-Infective Drugs Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 84: Asia Pacific - Anti-Infective Drugs Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 85: Asia Pacific - Anti-Infective Drugs Market Value Share Analysis, By Formulation, 2024 and 2035
Figure 86: Asia Pacific - Anti-Infective Drugs Market Attractiveness Analysis, By Formulation, 2025 to 2035
Figure 87: Asia Pacific - Anti-Infective Drugs Market Value Share Analysis, By Indication, 2024 and 2035
Figure 88: Asia Pacific - Anti-Infective Drugs Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 89: Asia Pacific - Anti-Infective Drugs Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 90: Asia Pacific - Anti-Infective Drugs Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Figure 91: Latin America - Anti-Infective Drugs Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 92: Latin America - Anti-Infective Drugs Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 93: Latin America - Anti-Infective Drugs Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 94: Latin America - Anti-Infective Drugs Market Value Share Analysis, By Drug Class, 2024 and 2035
Figure 95: Latin America - Anti-Infective Drugs Market Attractiveness Analysis, By Drug Class, 2025 to 2035
Figure 96: Latin America - Anti-Infective Drugs Market Value Share Analysis, By Drug Availability, 2024 and 2035
Figure 97: Latin America - Anti-Infective Drugs Market Attractiveness Analysis, By Drug Availability, 2025 to 2035
Figure 98: Latin America - Anti-Infective Drugs Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 99: Latin America - Anti-Infective Drugs Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 100: Latin America - Anti-Infective Drugs Market Value Share Analysis, By Formulation, 2024 and 2035
Figure 101: Latin America - Anti-Infective Drugs Market Attractiveness Analysis, By Formulation, 2025 to 2035
Figure 102: Latin America - Anti-Infective Drugs Market Value Share Analysis, By Indication, 2024 and 2035
Figure 103: Latin America - Anti-Infective Drugs Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 104: Latin America - Anti-Infective Drugs Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 105: Latin America - Anti-Infective Drugs Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Figure 106: Middle East & Africa - Anti-Infective Drugs Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 107: Middle East & Africa - Anti-Infective Drugs Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 108: Middle East & Africa - Anti-Infective Drugs Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 109: Middle East & Africa - Anti-Infective Drugs Market Value Share Analysis, By Drug Class, 2024 and 2035
Figure 110: Middle East & Africa - Anti-Infective Drugs Market Attractiveness Analysis, By Drug Class, 2025 to 2035
Figure 111: Middle East & Africa - Anti-Infective Drugs Market Value Share Analysis, By Drug Availability, 2024 and 2035
Figure 112: Middle East & Africa - Anti-Infective Drugs Market Attractiveness Analysis, By Drug Availability, 2025 to 2035
Figure 113: Middle East & Africa - Anti-Infective Drugs Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 114: Middle East & Africa - Anti-Infective Drugs Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 115: Middle East & Africa - Anti-Infective Drugs Market Value Share Analysis, By Formulation, 2024 and 2035
Figure 116: Middle East & Africa - Anti-Infective Drugs Market Attractiveness Analysis, By Formulation, 2025 to 2035
Figure 117: Middle East & Africa - Anti-Infective Drugs Market Value Share Analysis, By Indication, 2024 and 2035
Figure 118: Middle East & Africa - Anti-Infective Drugs Market Attractiveness Analysis, By Indication, 2025 to 2035
Figure 119: Middle East & Africa - Anti-Infective Drugs Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 120: Middle East & Africa - Anti-Infective Drugs Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035